Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by SanFrancisco99on Mar 18, 2015 4:49pm

250 Views

Post# 23535781

I Think This Supports A Phased Buyout Scenario

I think these paragraphs on valuation lend themselves very well to Phased Buyout scenarios with an upfront payment and future payments and royalties around various development milestones...

Based on our adjusted NPV valuation, we believe Resverlogix is substantially undervalued at the current share price of CAD 1.80. Using our valuation model, the Company’s current value is CAD 500 million, or CAD 5.85 per share. This represents an enormous upside from the current share price. The valuation is based on the development of its potential blockbuster RVX-208 and its purported early efficiency in reducing MACE.
With a successful Phase III trial and considering the market potential for RVX-208, we feel that a very significant upside potential for RVX-208 and Resverlogix is attainable. The next trial will help position RVX-208 to have a similar or even superior accretive value to other CVD novel agents such as CETP and PSCK9 inhibitors. Future data based from on a Phase III outcome trial, BETonMACE, will provide important additional data to build sensitivity and more detailed value proposition and Pharmacoeconomic models compared to other agents in development, CETP and PCSK9, which are currently underway in this important excess residual risk market of high risk CVD such as diabetes and CKD patients.

SOURCE: https://www.resverlogix.com/upload/media_element/208/01/leeuwenhoeck-research-initiation-report-rvx-march-16-2015.pdf